<DOC>
	<DOCNO>NCT00022516</DOCNO>
	<brief_summary>This randomize , phase III trial design test efficacy low-dose chemotherapy-maintenance regimen , hypothesize anti-angiogenic activity , administer follow standard chemotherapy patient early breast cancer whose tumor hormone receptor negative .</brief_summary>
	<brief_title>Low-dose Oral Cyclophosphamide Methotrexate Maintenance Hormone Receptor-negative Early Breast Cancer</brief_title>
	<detailed_description>PURPOSE : - Evaluate low-dose cyclophosphamide methotrexate chemotherapy-maintenance regimen early breast cancer . - Compare disease-free survival , overall survival , systemic disease-free survival patient treat regimen . - Compare toxic effect regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center , menopausal status ( pre v post ) , approve induction chemotherapy ( anthracycline cyclophosphamide v agent ) . Treatment duration 12 month low-dose chemotherapy-maintenance regimen ( CM-maintenance ) vs chemotherapy-maintenance regimen ( no-CM ) follow standard adjuvant chemotherapy . Patients randomize one two treatment arm . Patients follow every 6 month 5 year , yearly follow-up thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage I , II , III breast cancer T13 , N02 , M0 Patients sentinel node biopsy positive disease must undergo axillary dissection Tumor must confine breast without detected metastasis elsewhere T4 disease minimal dermal invasion allow No T4 disease ulceration skin , infiltration skin ( except pathologically minimal dermal involvement ) , peau d'orange , inflammatory breast cancer No bilateral breast cancer ( except situ carcinoma ) suspicious mass opposite breast proven benign No distant metastases No skeletal pain unknown cause , elevate alkaline phosphatase , bone scan show hot spot rule metastasis xray , MRI , and/or CT Must undergone prior total mastectomy OR breastconserving procedure ( e.g. , lumpectomy , quadrantectomy , partial mastectomy negative margin ) radiotherapy plan Patients must begin begin approved induction chemotherapy regimen within 8 week definitive surgery Negative surgical margin Axillary clearance least 6 lymph node examine OR negative sentinel node biopsy Known HER2 status immunohistochemistry fluorescence situ hybridization Hormone receptor status : Estrogen progesterone receptor negative Less 10 % positive tumor cell immunohistochemistry PATIENT CHARACTERISTICS : Age : Not specify Sex : Not specify Menopausal status : Premenopausal , define less 6 month since last menstrual period ( LMP ) AND prior bilateral ovariectomy AND estrogen replacement ( OR age 50 ) OR Postmenopausal , define prior bilateral ovariectomy OR 12 month since LMP without prior hysterectomy ( OR age 50 ) Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : See Disease Characteristics Bilirubin le 2.0 mg/dL ALT le 1.5 time upper limit normal OR AST le 60 IU/L Renal : Creatinine le 1.2 mg/dL Other : Not pregnant lactate within past 6 month Fertile patient must use effective barrier contraception No prior concurrent malignancy except adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix , contralateral ipsilateral situ breast carcinoma No psychiatric addictive disorder would preclude study No nonmalignant systemic disease would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Prior trastuzumab ( Herceptin ) allow Chemotherapy : See Disease Characteristics No prior adjuvant neoadjuvant chemotherapy breast cancer Endocrine therapy : No prior endocrine therapy breast cancer prevention No prior tamoxifen raloxifene breast cancer Radiotherapy : No prior radiotherapy breast cancer except primary irradiation Surgery : See Disease Characteristics Other : No prior preventative therapy breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
	<keyword>triple-negative breast cancer</keyword>
	<keyword>low-dose maintenance chemotherapy</keyword>
	<keyword>stroma</keyword>
	<keyword>angiogenesis</keyword>
</DOC>